TMED — EGF Theramed Health Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$1.59m
- CA$1.62m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -14.4 | -21.6 | -0.744 | -1.36 | -0.643 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 12.4 | 19.6 | -0.293 | 0.374 | 0.048 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.077 | 0.11 | 0.254 | -0.004 | 0.02 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -2.04 | -1.71 | -0.784 | -0.993 | -0.576 |
Capital Expenditures | -1.31 | -0.719 | 0 | — | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0.124 | -0.175 | 0.41 | 0 | — |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -1.18 | -0.894 | 0.41 | 0 | — |
Financing Cash Flow Items | — | -0.023 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 2.91 | 2.83 | 0.712 | 0.306 | 0.573 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.317 | 0.231 | 0.339 | -0.687 | -0.004 |